Autopsy report · NCT02346422

A Phase 1/2 Study of High-dose Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

“Sponsor has suspended clinical development of MYDICAR for heart failure.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• 9 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Celladon Corporation

Sponsor type

Industry

Conditions

Ischemic Cardiomyopathy; Non-ischemic Cardiomyopathy; Heart Failure; Cardiomyopathies

Interventions

MYDICAR Phase 1; MYDICAR Phase 2; Placebo Phase 2 only

Participants

9

Sites

4

Countries

United States

Trials that died the same way

• RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)
  “The sponsor's clinical program for the agent used in this study was discontinued.” (56% match in meaning)
• AcQMap® US Registry of Procedural and Long-term Clinical Outcomes (Discover-US)
  “Sponsor no longer performing clinical studies. Will only be a manufacturer” (56% match in meaning)
• A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension
  “Due to the sale of Cardene IV, the sponsor has stopped enrollment and withdrawn the study. No safety issues were identified.” (56% match in meaning)
• Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
  “Sponsor decision following clinical hold” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.